Klaria’s CEO Jesper Wiklund and the Chairman of the Board Fredrik Hubinette acquired shares in Klaria
Klaria’s CEO Jesper Wiklund and the Chairman of the Board Fredrik Hubinette both acquired shares in Klaria on Friday October 23rd, 2020. The trades were made on NASDAQ First North.
Klaria’s CEO Jesper Wiklund and the Chairman of the Board Fredrik Hubinette both acquired shares in Klaria on Friday October 23rd, 2020. The trades were made on NASDAQ Frist North. Jesper Wiklund acquired 25,164 shares at an average price of SEK 8.22, Fredrik Hubinette acquired 4,904 shares at an average price of SEK 8.15.
For more information, visit the Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99
This is Klaria Pharma Holding AB
Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.